Literature DB >> 7726609

Blood eosinophils, leukotriene C4 generation, and bronchial hyperreactivity in formerly preterm infants.

U Schauer1, S Alefsen, R Jäger, F Riedel, C H Rieger.   

Abstract

Infants born prematurely are known to display longstanding bronchial hyperreactivity. The mechanism responsible for this is still unclear. Eosinophils are thought to play a central part in the development of bronchial hyperreactivity in asthma. It was the aim of this study to assess the relation of bronchial hyperresponsiveness to potential markers of eosinophilic inflammation in peripheral blood. Eosinophil count, the concentration of serum eosinophilic cationic protein, the capacity of purified eosinophils to generate leukotriene C4, and bronchial reactivity was studied in 24 non-atopic children born prematurely, 12 healthy controls, and 12 children with asthma aged 6 to 9 years. There was no difference in serum concentrations on eosinophil cationic protein and eosinophil counts. However, eosinophils from the 15 formerly preterm infants with significant bronchial hyperreactivity generated significantly higher amounts of leukotriene C4 than normal controls and prematurely born children without bronchial hyperreactivity. Levels of leukotriene C4 in this group were comparable with those obtained with eosinophils from patients with asthma. In contrast with cells from the other groups, eosinophils from the children with bronchial hyperreactivity born prematurely show no enhancement of leukotriene C4 generation on prestimulation with platelet activating factor. It is concluded that bronchial hyperreactivity of children born prematurely is accompanied by the prestimulation of eosinophils.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7726609      PMCID: PMC1030086          DOI: 10.1136/adc.71.6.506

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  23 in total

1.  Potential role of eicosanoids and PAF in the pathophysiology of bronchopulmonary dysplasia.

Authors:  K R Stenmark; M Eyzaguirre; J Y Westcott; P M Henson; R C Murphy
Journal:  Am Rev Respir Dis       Date:  1987-09

2.  Measuring leukotrienes of slow reacting substance of anaphylaxis: development of a specific radioimmunoassay.

Authors:  E C Hayes; D L Lombardo; Y Girard; A L Maycock; J Rokach; A S Rosenthal; R N Young; R W Egan; H J Zweerink
Journal:  J Immunol       Date:  1983-07       Impact factor: 5.422

3.  Pulmonary function and bronchial hyperreactivity in long-term survivors of bronchopulmonary dysplasia.

Authors:  J A Smyth; E Tabachnik; W J Duncan; B J Reilly; H Levison
Journal:  Pediatrics       Date:  1981-09       Impact factor: 7.124

4.  Family history of asthma in infants with bronchopulmonary dysplasia.

Authors:  B G Nickerson; L M Taussig
Journal:  Pediatrics       Date:  1980-06       Impact factor: 7.124

5.  Preferential generation of leukotriene C4 by human eosinophils.

Authors:  R J Shaw; O Cromwell; A B Kay
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

6.  Long-term pulmonary sequelae of premature birth with and without idiopathic respiratory distress syndrome.

Authors:  A L Coates; H Bergsteinsson; K Desmond; E W Outerbridge; P H Beaudry
Journal:  J Pediatr       Date:  1977-04       Impact factor: 4.406

7.  CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy.

Authors:  C J Corrigan; A Haczku; V Gemou-Engesaeth; S Doi; Y Kikuchi; K Takatsu; S R Durham; A B Kay
Journal:  Am Rev Respir Dis       Date:  1993-03

8.  Skin eosinophilia in atopic patients.

Authors:  E Henocq; B B Vargaftig
Journal:  J Allergy Clin Immunol       Date:  1988-04       Impact factor: 10.793

9.  Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man.

Authors:  F M Cuss; C M Dixon; P J Barnes
Journal:  Lancet       Date:  1986-07-26       Impact factor: 79.321

10.  Recombinant human interleukin 5 is a selective activator of human eosinophil function.

Authors:  A F Lopez; C J Sanderson; J R Gamble; H D Campbell; I G Young; M A Vadas
Journal:  J Exp Med       Date:  1988-01-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.